fluxitra 110 mg tvrde kapsule
novatin limited, 230, second floor, eucharistic congress road, mosta, malta - dabigatraneteksilatmesilat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži 126,83 mg dabigatraneteksilata (u obliku mesilata), što odgovara 110 mg dabigatraneteksilata
fluxitra 150 mg tvrde kapsule
novatin limited, 230, second floor, eucharistic congress road, mosta, malta - dabigatraneteksilatmesilat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži 150 mg dabigatraneteksilata (u obliku dabigatraneteksilatmesilata)
fluxitra 75 mg tvrde kapsule
novatin limited, 230, second floor, eucharistic congress road, mosta, malta - dabigatraneteksilatmesilat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži 75 mg dabigatraneteksilata (u obliku dabigatraneteksilatmesilata)
vizilatan 50 mikrograma/ml kapi za oko, otopina
bausch + lomb ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - latanoprost - kapi za oko, otopina - 50 mikrograma/ml - urbroj: jedan ml otopine sadrži 50 mikrograma latanoprosta
xalatan 50 mikrograma/ml kapi za oko, otopina
upjohn eesv, rivium westlaan 142, capelle aan den ijssel, nizozemska - latanoprost - kapi za oko, otopina - 50 mikrograma/ml - urbroj: 1 ml otopine sadrži 50 mikrograma latanoprosta
namuscla
lupin europe gmbh - mexiletine hydrochloride - Миотонических poremećaja - srčana terapija - namuscla indiciran za simptomatsko liječenje миотонии u odraslih bolesnika s non-дистрофические миотонических poremećaja.
latapres 50 mikrograma/ml kapi za oko, otopina
bausch + lomb ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - latanoprost - kapi za oko, otopina - 50 mikrograma/ml - urbroj: jedan ml otopine kapi za oko sadrži 50 mikrograma latanoprosta
rivaroxaban accord
accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotska sredstva - prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 za hemodinamski nestabilne ТЭЛА pacijenata). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
herzuma 420 mg/1 bočica prašak za koncentrat za rastvor za infuziju
oktal pharma d.o.o. sarajevo - trastuzumab - prašak za koncentrat za rastvor za infuziju - 420 mg/1 bočica - 1 bočica sadrži: 420 mg trastuzumaba
herzuma 150 mg/1 bočica prašak za koncentrat za rastvor za infuziju
oktal pharma d.o.o. sarajevo - trastuzumab - prašak za koncentrat za rastvor za infuziju - 150 mg/1 bočica - jedna bočica sadrži: 150 mg trastuzumaba